Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856887 | 1.00 | ESR1 (0.60) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6850404 | 1.00 | ESR1 (0.60) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6850603 | 0.98 | ESR1 (0.57) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6395550 | 0.98 | ESR1 (0.61) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6390316 | 0.98 | ESR1 (0.61) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7784538 | 0.98 | ESR1 (0.61) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL8596397 | 0.97 | ESR1 (0.60) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6291885 | 0.97 | ESR1 (0.60) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6292098 | 0.97 | ESR1 (0.60) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6296762 | 0.97 | ESR1 (0.60) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6830859-B2 | Electrostatic latent images; containing barium salt of sulfoisophthalic acid | RICOH COMPANY, LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| US-20030077534-A1 | Charge control agent and toner using same | RICOH COMPANY, LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030077534-A1 | Charge control agent and toner using same | BET1, SMARCA5, SMARCA1 | ESR1 3688/4885AKR1C4 3735/4885AKR1C3 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.